Daphne W. Bell

42.4k total citations · 13 hit papers
86 papers, 32.2k citations indexed

About

Daphne W. Bell is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daphne W. Bell has authored 86 papers receiving a total of 32.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 37 papers in Oncology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daphne W. Bell's work include Lung Cancer Treatments and Mutations (20 papers), Cancer-related Molecular Pathways (13 papers) and Cancer Genomics and Diagnostics (13 papers). Daphne W. Bell is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Cancer-related Molecular Pathways (13 papers) and Cancer Genomics and Diagnostics (13 papers). Daphne W. Bell collaborates with scholars based in United States, Canada and Japan. Daphne W. Bell's co-authors include Daniel A. Haber, Jeffrey Settleman, Raffaella Sordella, Masaki Okano, En Li, Thomas J. Lynch, Brian W. Brannigan, Ross A. Okimoto, Patricia L. Harris and Sreenath V. Sharma and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Daphne W. Bell

85 papers receiving 31.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 8.9k citations Thomas J. Lynch, Daphne W. Bell et al. profile →
DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development

1999 4.5k citations Daphne W. Bell, Daniel A. Haber et al. Cell profile →
Isolation of rare circulating tumour cells in cancer patients by microchip technology

2007 2.9k citations Lecia V. Sequist, Daphne W. Bell et al. profile →
Epidermal growth factor receptor mutations in lung cancer

2007 2.5k citations Sreenath V. Sharma, Daphne W. Bell et al. Nature reviews. Cancer profile →
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

2004 1.3k citations Raffaella Sordella, Daphne W. Bell et al. Science profile →
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

2008 1.3k citations Lecia V. Sequist, Lindsey Ulkus et al. profile →
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 774 citations Eunice L. Kwak, Raffaella Sordella et al. Proceedings of the National Academy of Sciences profile →
salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines

2002 723 citations Nicolas Tapon, Kieran F. Harvey et al. Cell profile →
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

1995 691 citations Daphne W. Bell, Joseph R. Testa et al. profile →
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome

1999 662 citations Daphne W. Bell, Doke C.R. Wahrer et al. Science profile →
BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function

2001 541 citations Daphne W. Bell, Doke C.R. Wahrer et al. Cell profile →
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

2005 518 citations Daphne W. Bell, Thomas J. Lynch et al. profile →
Clinical actionability of molecular targets in endometrial cancer

2019 293 citations Mary Ellen Urick, Daphne W. Bell Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Daphne W. Bell

Since Specialization

Citations

This map shows the geographic impact of Daphne W. Bell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daphne W. Bell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daphne W. Bell more than expected).

Fields of papers citing papers by Daphne W. Bell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daphne W. Bell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daphne W. Bell. The network helps show where Daphne W. Bell may publish in the future.

Co-authorship network of co-authors of Daphne W. Bell

This figure shows the co-authorship network connecting the top 25 collaborators of Daphne W. Bell. A scholar is included among the top collaborators of Daphne W. Bell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daphne W. Bell. Daphne W. Bell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High‐risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels 2021 ·Cancer ·Mary Ellen Urick, Eun‐Jeong Yu, Daphne W. Bell	10
2	Proteomic profiling of FBXW7‐mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target 2020 ·Cancer Medicine ·Mary Ellen Urick, Daphne W. Bell	9
3	High-resolution copy number analysis of clear cell endometrial carcinoma 2019 ·Cancer Genetics ·Andrea O’Hara, Matthieu Le Gallo, Meghan L. Rudd, Daphne W. Bell	7
4	Clinical actionability of molecular targets in endometrial cancer breakdown → 2019 ·Nature reviews. Cancer ·Mary Ellen Urick, Daphne W. Bell	293
5	In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI‐2 and dinaciclib 2018 ·Molecular Carcinogenesis ·Mary Ellen Urick, Daphne W. Bell	13
6	Recurrent patterns of DNA methylation in theZNF154,CASP8, andVHLpromoters across a wide spectrum of human solid epithelial tumors and cancer cell lines 2013 ·Epigenetics ·Francisco Sánchez-Vega, Valer Gotea, Hanna M. Petrykowska, Gennady Margolin, Thomas C. Krivak, Julie A. DeLoia, Daphne W. Bell, Laura Elnitski	48
7	The genomics and genetics of endometrial cancer 2012 ·PubMed ·Daphne W. Bell, (unknown)	92
8	A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas 2011 ·Clinical Cancer Research ·Meghan L. Rudd, Jessica C. Price, Sarah Fogoros, Andrew K. Godwin, Dennis C. Sgroi, Maria J. Merino, Daphne W. Bell	170
9	PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer 2011 ·Cancer Research ·Mary Ellen Urick, Meghan L. Rudd, Andrew K. Godwin, Dennis C. Sgroi, Maria J. Merino, Daphne W. Bell	162
10	A Novel Wilms Tumor 1 (WT1) Target Gene Negatively Regulates the WNT Signaling Pathway 2010 ·Journal of Biological Chemistry ·Myoung Shin Kim, Seung Kew Yoon, Frank Bollig, Jirouta Kitagaki, Wonhee Hur, (unknown), Yunping Wu, Miguel N. Rivera, (unknown), (unknown), Karim Malik, Daphne W. Bell, Christoph Englert, Alan O. Perantoni, Sean Bong Lee	83
11	Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin 2009 ·Molecular Cancer Research ·Jianmin Zhang, Young‐Han Song, Brian W. Brannigan, Doke C.R. Wahrer, Taryn A. Schiripo, Patricia L. Harris, Sara M. Haserlat, Lindsey E. Ulkus, Kristen Shannon, Judy E. Garber, Matthew L. Freedman, Brian E. Henderson, Lee Zou, Dennis C. Sgroi, Daniel A. Haber, Daphne W. Bell	12
12	An X Chromosome Gene, WTX , Is Commonly Inactivated in Wilms Tumor 2007 ·Science ·Miguel N. Rivera, Woo‐Jae Kim, Julie Wells, David R. Driscoll, Brian W. Brannigan, Moonjoo Han, James C. Kim, Andrew P. Feinberg, William L. Gerald, Sara O. Vargas, Lynda Chin, A. John Iafrate, Daphne W. Bell, Daniel A. Haber	225
13	Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib 2007 ·Cancer Research ·Roseann Mulloy, Audrey Ferrand, Young‐Joo Kim, Raffaella Sordella, Daphne W. Bell, Daniel A. Haber, Karen S. Anderson, Jeffrey Settleman	150
14	Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation 2007 ·Cancer Research ·Nadia Godin-Heymann, (unknown), Miguel N. Rivera, Lindsey Ulkus, Daphne W. Bell, David J. Riese, Jeffrey Settleman, Daniel A. Haber	120
15	Frequent Met Oncogene Amplification in a Brca1/Trp53 Mouse Model of Mammary Tumorigenesis 2006 ·Cancer Research ·Gromoslaw A. Smolen, Beth Muir, Gayatry Mohapatra, Anne Barmettler, Woo Jae Kim, Miguel N. Rivera, Sara M. Haserlat, Ross A. Okimoto, Eunice L. Kwak, Sonika Dahiya, Judy E. Garber, Daphne W. Bell, Dennis C. Sgroi, Lynda Chin, Chu‐Xia Deng, Daniel A. Haber	32
16	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib 2006 ·Clinical Cancer Research ·David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal I. Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balázs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne	491
17	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib breakdown → 2005 ·Proceedings of the National Academy of Sciences ·Eunice L. Kwak, Raffaella Sordella, Daphne W. Bell, Nadia Godin-Heymann, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, David R. Driscoll, Panos Fidias, Thomas J. Lynch, Sridhar K. Rabindran, John P. McGinnis, Allan Wissner, Sreenath V. Sharma, Kurt J. Isselbacher, Jeffrey Settleman, Daniel A. Haber	774
18	Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways breakdown → 2004 ·Science ·Raffaella Sordella, Daphne W. Bell, Daniel A. Haber, Jeffrey Settleman	1337
19	salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines breakdown → 2002 ·Cell ·Nicolas Tapon, Kieran F. Harvey, Daphne W. Bell, Doke C.R. Wahrer, Taryn A. Schiripo, Daniel A. Haber, Iswar K. Hariharan	723
20	Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. 1998 ·PubMed ·Naomi Laing, Martin G. Belinsky, Gary D. Kruh, Daphne W. Bell, Jonathan T. Boyd, Linda R. Barone, Joseph R. Testa, Kenneth D. Tew	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact